• Eupraxia Pharmaceuticals will hold its annual general meeting on June 18, 2026 via virtual webcast.
• Shareholders will review the audited financial statements for the years ended Dec. 31, 2025 and 2024.
• Items for vote include setting the board size at seven, electing directors, appointing KPMG LLP as auditor, authorizing auditor remuneration.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eupraxia Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001171843-26-003787), on May 29, 2026, and is solely responsible for the information contained therein.